rability of mk-0518 a Novel Inhibitor of hiv-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive hiv-1-Infected Individuals. J Acquir Immune Defic Syndr, 5: 509-515. Mbisa, J.L., Martin, S.A. y Cane, P.A. (2011). Patterns of Resistance development with Integrase Inhibitors in hiv. Infect Drug Res, 4: 65-76. Mocarski, E.S., Shank, T. y Pass, R.F. (2007). Cytomegaloviruses. En Knipe, M., Howley, P.M., Griffin, D.E., Lamb, R.A., Martin, M.A., Roizman, B. y Straus, S.E. (Eds.), Fields Virology. (5a Ed., Vol. 2). Filadelfia, PA: Lippincott-Williams & Wilkins. Pp. 2701-2772. Morrison, D., Roy, S., Rayner, C., Amer, A., Howard, D., Smith, J.R. y Eva, T.G. (2008). A randomized, crossover study to evaluate the Pharmacokinetics of Amantadine and Oseltamivir administered alone and in combination. plos one 2(12): e1305. Munir, S., Saleem, S., Idrees, M., Tariq, A., Butt, S., Rauff, B., Hussain, A., Badar, S., Naudhani, M., Fatima, Z., Ali, M., Ali, L., Akram, M., Aftab, M., Khubaib, B. y Awan, Z. (2010). Hepatitis C Treatment: Current and future perspectives. Virol J, 7: 296. Nijhuis, M., Van Maarseveen, N., De Jong, D., Schipper, P., Goedegebuure, I. y Boucher, C. (2006). Substitutions within Gag but outside the cleavage sites can cause Protease Inhibitor Resistance. Antivir Ther, 11: S149. Ogburn, E.T., Jones, D.R., Masters, A.R., Xu, C., Guo, Y. y Desta, Z. (2010). Efavirenz primary and secondary Metabolism in vitro and in vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the principal catalyst of Efavirenz 7-Hydroxylation. Drug Metab Dispos, 38(7): 1218-1229. Ogungbenro, K., Matthews, I., Looby, M., Kaiser, G., Graham, G. y Aarons, L. (2009). Population Pharmacokinetics and optimal design of Paediatric studies for Famciclovir. Br J Clin Pharmacol, 68(4): 546-560. Otomo, K., Toyama, A., Miura, T. y Takeuchi, H. (2009). Interactions between histidine and tryptophan residues in the bm2 proton channel from influenza B virus. J Biochem, 145(4): 543-554. Perrottet, N., Decosterd, L.A., Meylan, P., Pascual, M., Biollaz, J. y Buclin, T. (2009). Valganciclovir in Adult solid organ transplant recipients: Pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokin, 48(6): 399-418. Peiris, J.S.M., De Jong, M.D. y Guan, Y. (2007). Avian influenza virus (H5N1): A threat to human health. Clin Microbiol Rev, 20(2): 243-267. Pendri, A., Meanwell, N.A., Peese, K.M. y Walker, M.A. (2011). New first and second generation inhibitors of human immunodeficiency virus-1 integrase. Expert Opin Ther Pat, 21(8): 1173-1189. Poordad, F. y Chee, G.M. (2010). Viral Resistance in Hepatitis B: Prevalence and Management. Curr Gastroenterol Rep, 12: 62-69. Powderly, W.G. (2010). Integrase inhibitors in the treatment of hiv-1 infection. J Antimicrob Chemother, 65: 2485-2488. Prada, N. y Markowitz, M. (2010). Novel integrase inhibitors for hiv. Expert Opin Investig Drugs 19(9): 1087-1098. Puthavathana, P., Sangsiriwut, K., Korkusol, A., Pooruk, P., Auewarakul, P., Pittayawanganon, C., Sutdan, D., Kitphati, R., Sawanpanyalert, P., Phommasack, B., Bounlu, K. y Ungchusak, K. (2009). Avian influenza virus (H5N1) in human, Laos. Emerg Infect Dis, 15(1): 127-129. Rameix-Welti, A-M., Enouf, V., Cuvelier, F., Jeannin, P., Van der Werf, S. (2008). Enzymatic properties of the neuraminidase of seasonal
210
MANUAL DE FARMACOLOGĂ?A DE LAS INFECCIONES, MICOSIS, PARASITOSIS Y NEOPLASIAS